BIOLASE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.148 USD | 0.00% |
|
+6.47% | -86.81% |
| Sales 2024 * | 51.5M 4.29B | Sales 2025 * | 55.5M 4.63B | Capitalization | 4.92M 410M |
|---|---|---|---|---|---|
| Net income 2024 * | -8M -667M | Net income 2025 * | -5M -417M | EV / Sales 2024 * | 0.1 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.09 x |
| P/E ratio 2024 * |
-0.46
x | P/E ratio 2025 * |
-1.35
x | Employees | 157 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on BIOLASE, Inc.
More recommendations
More press releases
| 1 week | +6.47% | ||
| Current month | -22.02% | ||
| 1 month | -7.67% | ||
| 3 months | -83.37% | ||
| 6 months | -91.03% | ||
| Current year | -86.81% |
1 week
0.14
0.16
1 month
0.130.21
Current year
0.131.19
1 year
0.1332.09
3 years
0.132 348.50
5 years
0.135 650.00
10 years
0.1337 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
John Beaver
CEO | Chief Executive Officer | 62 | 01/17/01 |
| Director of Finance/CFO | 53 | 01/21/01 | |
Steven Sandor
COO | Chief Operating Officer | 44 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jonathan Lord
CHM | Chairman | 69 | 01/14/01 |
John Beaver
CEO | Chief Executive Officer | 62 | 01/17/01 |
| Director/Board Member | 73 | 16/21/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.148 | 0.00% | 688,002 |
| 25/24/25 | 0.148 | +2.78% | 626,004 |
| 24/24/24 | 0.144 | -4.70% | 546,367 |
| 23/24/23 | 0.1511 | +0.73% | 786,586 |
| 22/24/22 | 0.15 | +7.91% | 1,455,637 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.
Calendar
02/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.148
USD
Average target price
1.633
USD
Spread / Average Target
+1,003.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -86.81% | 4.92M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- BIOL Stock
